Evidence map›Paper›PMID 26292291›Full record

Trial reportJournal of clinical microbiology2015

Association of Human Papillomavirus 31 DNA Load with Risk of Cervical Intraepithelial Neoplasia Grades 2 and 3.

Xia Liu, Mark Schiffman, Ayaka Hulbert, Zhonghu He, Zhenping Shen, Laura A Koutsky, Long Fu Xi

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. False positive cervical HPV screening test results.Papillomavirus research (Amsterdam, Netherlands) · 2019
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xia LiuDepartment of Pathology, School of Medicine, University of Washington, Seattle, Washington, USA Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, Liaoning, People's Republic of China.
Mark SchiffmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Ayaka HulbertDepartment of Pathology, School of Medicine, University of Washington, Seattle, Washington, USA.
Zhonghu HeKey Laboratory of Carcinogenesis and Translational Research, Peking University School of Oncology, Beijing, People's Republic of China.
Zhenping ShenDepartment of Pathology, School of Medicine, University of Washington, Seattle, Washington, USA.
Laura A KoutskyDepartment of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA.
Long Fu XiDepartment of Pathology, School of Medicine, University of Washington, Seattle, Washington, USA Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA longfu@u.washington.edu.

Funding

Intratypic variation of oncogenic HPV types as a risk factor for cervical neoplasR01CA133569 · NCI · UNIVERSITY OF WASHINGTON · PI XI, LONG FU · 2009 to 2012
$1.7M
NCI NIH HHS CA133569NCI NIH HHS R01 CA133569
6 · The paper itself

Abstract

The association between human papillomavirus 31 (HPV31) DNA loads and the risk of cervical intraepithelial neoplasia grades 2 and 3 (CIN2-3) was evaluated among women enrolled in the atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesion (LSIL) triage study (ALTS), who were monitored semiannually over 2 years and who had HPV31 infections detected at ≥1 visit. HPV31 DNA loads in the first HPV31-positive samples and in a random set of the last positive samples from women with ≥2 HPV31-positive visits were measured by a real-time PCR assay. CIN2-3 was histologically confirmed at the same time as the first detection of HPV31 for 88 (16.6%) of 530 women. After adjustment for HPV31 lineages, coinfection with other oncogenic types, and the timing of the first positive detection, the odds ratio (OR) per 1-log-unit increase in viral loads for the risk of a concurrent diagnosis of CIN2-3 was 1.5 (95% confidence interval [CI], 1.2 to 1.9). Of 373 women without CIN2-3 at the first positive visit who had ≥1 later visit, 44 had subsequent diagnoses of CIN2-3. The initial viral loads were associated with CIN2-3 diagnosed within 6 months after the first positive visit (adjusted OR, 1.5 [95% CI, 1.0 to 2.4]) but were unrelated to CIN2-3 diagnosed later. For a random set of 49 women who were tested for viral loads at the first and last positive visits, changes in viral loads were upward and downward among women with and without follow-up CIN2-3 diagnoses, respectively, although the difference was not statistically significant. Results suggest that HPV31 DNA load levels at the first positive visit signal a short-term but not long-term risk of CIN2-3.

Indexed as

Atypical Squamous Cells of the CervixBiomarkers, TumorColposcopyDNA, ViralFemaleHuman papillomavirus 31HumansNeoplasm GradingPapillomavirus InfectionsReal-Time Polymerase Chain ReactionUterine Cervical DysplasiaUterine Cervical NeoplasmsViral LoadBiomarkers, TumorDNA, Viral

Identifiers

PMID26292291
PMCPMC4609706

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.